Uli Bialucha
Chief Scientific Officer Xilio Therapeutics Inc.
Dr. Bialucha is a passionate life science leader with more than 15 years of experience in oncology/immuno-oncology drug discovery and preclinical development. Dr. Bialucha has served as Xilio’s chief scientific officer since August 2022 and joined Xilio as the senior vice president of research in April 2021, advancing Xilio’s clinically validated masking technology towards new applications in the context of bi- and multispecific biologics. He joined Xilio from Immunitas Therapeutics where he served as vice president of drug discovery. Prior to joining Immunitas, Dr. Bialucha he spent over 9 years in roles of increasing responsibility at the Novartis Institutes for Biomedical Research, most recently leading the oncology biotherapeutics group, where he directed multiple programs towards successful entry into clinical development across a variety of modalities including ADCs, TCEs and radioligand therapy. Dr. Bialucha received his B.S. in molecular genetics from the University of Sussex and his Ph.D. in molecular cell biology from the MRC Laboratory for Molecular Cell Biology, University College London. He completed his postdoctoral training in Professor Scott Lowe’s laboratory at Cold Spring Harbor Laboratory.
Seminars
- Xilio is deploying its clinically validated masking technology to advance several highly differentiated bi- and multispecific molecules towards clinical development
- XTX501, Xilio’s PD1/masked IL-2 bispecific has the potential to be a foundational backbone therapy for combination regimens across a broad range of solid tumors, and the program is on track to advance into the clinic this year
- XTX601, Xilio’s masked CLDN18.2 T-cell engager and Xilio’s masked PSMA+STEAP1 dual-TAA targeted T-cell engager with co-stimulation both have firstin- class potential and further demonstrate the power of our masking technology to unlock the potential of T-cell engagers
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology
